CASI Pharmaceuticals (CASI) Stock Statistics & Valuation Metrics

CASI Pharmaceuticals has a market cap or net worth of $31.76M. The enterprise value is $49.89M.

CASI Pharmaceuticals has 15,492,681 shares outstanding. The number of shares has decreased by -2.65% in one year.

CASI Pharmaceuticals’s return on equity (ROE) is -1.11 and return on invested capital (ROIC) is -42.18%.

The current PE Ratio of CASI Pharmaceuticals is -3.55. CASI Pharmaceuticals’s PEG ratio is 0.12.

In the last 12 months, CASI Pharmaceuticals had revenue of 33.88M and earned -26.94M in profits. Earnings per share was -2.02.

In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.

CASI Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

CASI Pharmaceuticals upcoming earnings date is May 14, 2025, TBA Not Confirmed.

CASI Pharmaceuticals as a current ratio of 3.55, with Debt / Equity ratio of 138.10%

In the past 12 months, CASI Pharmaceuticals has paid -81.00K in taxes.

CASI Pharmaceuticals EV to EBITDA ratio is -4.63, with an EV/FCF ratio of -4.49.

CASI Pharmaceuticals has $20.81M in cash and marketable securities with $7.24M in debt, giving a net cash position of -$1.69M billion.

Gross margin is 55.18%, with operating margin of -74.03%, and net profit margin of -79.51%.

The average price target for CASI Pharmaceuticals is $4.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy